Keyphrases
Tumor
69%
Overall Survival
60%
Chemotherapy
50%
Phase II Study
50%
Non-small Cell Lung Cancer (NSCLC)
48%
Progression-free Survival
41%
Breast Cancer
40%
Phase II Trial
40%
Confidence Interval
38%
Relapsed or Refractory
30%
Rituximab
28%
Clinical Trials
28%
Lung Cancer
23%
Mantle Cell Lymphoma
22%
Metastatic Breast Cancer
21%
Targeted Therapy
21%
Hazard Ratio
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Doxorubicin
20%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Radiation Therapy
19%
Follicular Lymphoma
18%
In Cancer
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
18%
Brentuximab Vedotin
18%
Adverse Events
17%
Cisplatin
16%
Complete Response
16%
Triple-negative Breast Cancer
16%
Gemcitabine
16%
Docetaxel
15%
Programmed Death-ligand 1 (PD-L1)
15%
Partial Response
15%
NCCN Guidelines
15%
Pancreatic Cancer
15%
Clinical Outcomes
15%
Oncology
15%
Lymphoma
14%
Overall Response Rate
14%
Hodgkin Lymphoma
14%
T Cells
14%
Colorectal Cancer
14%
Carboplatin
14%
Median Overall Survival
14%
Non-Hodgkin Lymphoma
13%
Older Adults
13%
Pembrolizumab
13%
Immune Checkpoint Inhibitors
13%
Phase I Study
13%
Median Progression-free Survival
13%
Bevacizumab
12%
Solid Tumors
12%
Paclitaxel
12%
Cyclophosphamide
12%
Circulating Tumor DNA (ctDNA)
12%
Randomized Phase II Trial
12%
Previously Treated
12%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
12%
Pancreatic Ductal Adenocarcinoma
12%
Melanoma
12%
Placebo
11%
Glioblastoma
11%
High Risk
11%
Response Rate
11%
Small Cell Lung Cancer
11%
Stable Disease
11%
Sarcoma
11%
Whole Genome
11%
Tumor Cells
11%
Disease Progression
11%
Monotherapy
10%
Neutropenia
10%
Objective Response Rate
10%
Peripheral T-cell Lymphoma
10%
Metastasis
10%
Chronic Lymphocytic Leukemia
10%
Maximum Tolerated Dose
10%
Pan-cancer Analysis
10%
Older Patients
10%
Prednisone
10%
Soft Tissue Sarcoma
10%
Cetuximab
10%
Multiple Myeloma
10%
Radiotherapy
9%
Antitumor Activity
9%
Dose Escalation
9%
Systemic Therapy
9%
Treatment Options
9%
Neoadjuvant
9%
Cancer Treatment
9%
Newly Diagnosed
9%
Etoposide
9%
Malignancy
9%
Colorectal Liver Metastases
9%
Resection
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Head-and-neck Cancer
9%
Tumor Microenvironment
9%
Bortezomib
9%
Leukemia
9%
Medicine and Dentistry
Neoplasm
100%
Diseases
67%
Malignant Neoplasm
64%
Breast Cancer
61%
Overall Survival
60%
Non Small Cell Lung Cancer
41%
Progression Free Survival
39%
Clinical Trial
32%
Oncology
30%
Cancer
28%
Radiation Therapy
27%
Lung Cancer
27%
Immunotherapy
26%
Metastatic Carcinoma
25%
Rituximab
24%
Targeted Therapy
20%
Mantle Cell Lymphoma
19%
Hodgkin's Lymphoma
19%
Recurrent Disease
19%
Adverse Event
18%
Arm
18%
Surgery
18%
Diffuse Large B-Cell Lymphoma
17%
Non-Hodgkin Lymphoma
17%
Biological Marker
17%
T Cell
16%
Melanoma
16%
Hazard Ratio
15%
Connective Tissue Cancer
14%
Doxorubicin
13%
Metastatic Breast Cancer
13%
Transplantation
13%
Cisplatin
13%
Immunity
12%
Follicular Lymphoma
12%
Phase II Trials
12%
Triple Negative Breast Cancer
12%
Brentuximab Vedotin
12%
Colorectal Carcinoma
12%
Pancreas Cancer
11%
Pembrolizumab
11%
Prostate Cancer
11%
Small Cell Lung Cancer
11%
Systemic Therapy
11%
Paclitaxel
11%
Soft Tissue Sarcoma
10%
Cyclophosphamide
10%
Pancreas Adenocarcinoma
10%
Positron Emission Tomography
10%
Solid Malignant Neoplasm
10%
Immune Checkpoint Inhibitor
10%
Tumor Progression
10%
Peripheral T-Cell Lymphoma
10%
Gemcitabine
10%
Placebo
10%
Cancer Therapy
9%
Circulating Tumor DNA
9%
Chemoradiotherapy
9%
Cancer Cell
9%
Hormone Therapy
9%
Glioblastoma
9%
Quality of Life
9%
B Cell
8%
Epidermal Growth Factor Receptor
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Multiple Myeloma
8%
Carboplatin
8%
Tumor Cell
8%
Head and Neck Squamous Cell Carcinoma
8%
Classical Hodgkin Lymphoma
8%
Human Immunodeficiency Virus
8%
Neoadjuvant Chemotherapy
7%
Systematic Review
7%
Clear Cell Renal Cell Carcinoma
7%
Colorectal Liver Metastasis
7%
Bevacizumab
7%
Hematopoietic Cell
7%
B-Cell Lymphoma
7%
Survival Rate
7%
Squamous Cell Carcinoma
7%
Vincristine
6%
Ibrutinib
6%
Adjuvant Chemotherapy
6%
Disease Exacerbation
6%
Bendamustine
6%
Prognostic Factor
6%
Lenalidomide
6%
Transitional Cell Carcinoma
6%
Nivolumab
6%
Rectum Cancer
6%
Diagnosis
6%
Cetuximab
6%
Health Care Cost
6%
Disease Free Survival
6%
Monotherapy
6%
Head and Neck Cancer
6%
Primary Tumor
6%
Etoposide
6%
Prednisone
6%
Macrophage
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
76%
Chemotherapy
66%
Diseases
59%
Malignant Neoplasm
57%
Overall Survival
55%
Progression Free Survival
45%
Non Small Cell Lung Cancer
45%
Breast Cancer
32%
Rituximab
31%
Clinical Trial
28%
Adverse Event
27%
Lung Cancer
25%
Paclitaxel
21%
Doxorubicin
21%
Nonhodgkin Lymphoma
20%
Phase II Trials
19%
Solid Malignant Neoplasm
18%
Metastatic Breast Cancer
17%
Follicular Lymphoma
16%
Mantle Cell Lymphoma
15%
Diffuse Large B Cell Lymphoma
15%
Cisplatin
15%
Immunotherapy
15%
Prostate Cancer
15%
Docetaxel
15%
Carboplatin
14%
Cyclophosphamide
14%
Biological Marker
14%
Small Cell Lung Cancer
13%
Gemcitabine
13%
Placebo
13%
Recurrent Disease
12%
Hodgkin Disease
12%
Epidermal Growth Factor Receptor
12%
Chemoradiation Therapy
11%
Bevacizumab
11%
Metastasis
10%
Pharmacokinetics
10%
Glioblastoma
10%
Remission
10%
Neutropenia
10%
Colorectal Carcinoma
10%
Monotherapy
9%
Melanoma
9%
Brentuximab Vedotin
9%
Etoposide
9%
Bendamustine
9%
Cetuximab
9%
Vincristine
9%
Maximum Tolerated Dose
9%
Pembrolizumab
9%
Pancreas Cancer
8%
Prednisone
8%
Soft Tissue Sarcoma
8%
Triple Negative Breast Cancer
8%
Head and Neck Squamous Cell Carcinoma
8%
Antitumor Activity
8%
Pancreas Adenocarcinoma
8%
Tumor Growth
8%
Chronic Lymphatic Leukemia
8%
Bortezomib
7%
Tolerability
7%
Survival Rate
7%
Disease Exacerbation
7%
Lenalidomide
7%
Leukemia
7%
Immune Checkpoint Inhibitor
7%
Pemetrexed
7%
Diarrhea
6%
Renal Cell Carcinoma
6%
Receptor
6%
Thrombocytopenia
6%
Connective Tissue Cancer
6%
Transitional Cell Carcinoma
6%
Erlotinib
6%
Peripheral T Cell Lymphoma
5%
Anemia
5%
Squamous Cell Carcinoma
5%
Phosphatidylinositol 3 Kinase
5%
Disease Free Survival
5%
Everolimus
5%
Carcinogenesis
5%
Castration Resistant Prostate Cancer
5%
Liver Cell Carcinoma
5%
Monoclonal Antibody
5%
Ibrutinib
5%
Methotrexate
5%
Head and Neck Cancer
5%
Phase I Trials
5%
Estrogen Receptor
5%
Irinotecan
5%
Circulating Tumor DNA
5%
Combination Therapy
5%
Multiple Myeloma
5%
Nausea
5%
Palbociclib
5%
Nivolumab
5%
Endocrine Therapy
5%
Temozolomide
5%
Febrile Neutropenia
5%